A vial that contains three peptides is a harder analytical problem than a vial that contains one. This article is a reference on how multi-peptide blends are analysed: what a reverse-phase HPLC run has to separate, how purity should be reported when there is more than one intended component, how each component’s identity is confirmed by mass, and what a blend certificate should list. It makes no claim about what any of the compounds do and contains no preparation, handling or dosing guidance.
Why a blend is a different analytical problem
With a single peptide, the chromatogram has one intended main peak and everything else is, by definition, impurity. Purity is that peak’s share of the total integrated area at the chosen wavelength. With a blend there are two or three intended peaks, and the familiar single purity number stops being meaningful on its own. “98% pure” for a blend could mean that the intended peaks together make up 98% of the total area, that each component was 98% pure as a raw material before blending, or that the weakest component reaches 98%. Those are different claims, and a certificate should say which one it is making.
The two blends supplied here show the range. The BPC-157 + TB500 + MGF blend is listed at 18.5mg per vial, made up of 10mg BPC-157, 7.5mg TB500 and 1mg MGF. The CJC-1295 + Ipamorelin blend is listed at 10mg per vial, 5mg of each. An even two-way split and an uneven three-way split, with one minor component at a little over 5% of the stated total, pose different analytical challenges.
Separating the components on reverse-phase HPLC
Reverse-phase HPLC separates peptides by hydrophobicity: each is retained on a C18 column until the organic fraction of the mobile phase rises far enough to release it. Peptides of different length and composition usually elute at different times, which is what makes a blend analysable in a single run. Not always, though: two components can co-elute, leaving the column at nearly the same time so that their peaks overlap or merge.
A competent method for a blend is developed so that every intended component is resolved from the others and from the principal impurities of each. In practice that means a gradient shallow enough across the region where the components elute, rather than a fast generic ramp, and a retention time reported for each component. The chromatogram should let a reader see that the peaks are separate; visible baseline between them is worth more than a table of numbers. Our guide to reading an HPLC chromatogram covers what resolution looks like on a trace.
Detection wavelength needs the same thought it does for single peptides. At around 214 nm the peptide bond absorbs, so every component is seen. At 280 nm only components containing tryptophan or tyrosine absorb meaningfully, so a 280 nm trace can under-represent a component or miss it entirely. For a blend, a low wavelength such as 214 nm is the sensible basis for the purity read.
Per-component purity versus total area
There are two honest ways to report the purity of a blend, and one unhelpful one.
- Summed purity. The combined area of all intended component peaks as a percentage of total integrated area. It answers the question “how much of what was detected was meant to be there”, but an impurity belonging to the smallest component can disappear into the sum.
- Per-component purity. Each component judged against the impurities that belong to it, often established by analysing each raw material separately before blending. This is the more informative figure, because it shows whether any one component is weak.
- The unhelpful version is a single number with no statement of which of the above it represents.
Area percentages also do not translate directly into mass proportions. Different peptides absorb ultraviolet light differently per milligram, because absorbance at low wavelength depends on the number of peptide bonds and on particular side chains. A component that is just over half the stated mass may be more or less than half the total peak area. Where a certificate reports component ratios, it should say whether they come from calibrated reference standards or from raw area.
Confirming the mass of each component
Retention time alone does not prove identity, and that is especially true in a blend, where a peak can be assigned to the wrong component. Mass spectrometry closes the gap. An LC-MS run, or MS on collected fractions, should show an observed mass matching the expected mass of each intended component — one confirmation per peptide, not one for the vial. A three-component blend needs three mass confirmations. A certificate that confirms one mass and is silent on the others has confirmed one component.
The minor component deserves particular attention. When one peptide makes up a small share of the stated total, as MGF does in the 18.5mg blend, its signal is small beside the others and easier to miss or misattribute. It is reasonable to expect its observed mass to be reported explicitly.
Why net content per component matters
Every lyophilised peptide carries non-peptide mass: counter-ion left from purification, usually trifluoroacetate or acetate, and residual water. Net peptide content is the fraction of the powder that is actually peptide. In a single-peptide vial that is one number. In a blend it can differ from one component to the next, because each peptide was synthesised, purified and isolated as a salt separately, and the amount of counter-ion each carries depends on its own basic residues and size.
The consequence is that stated component masses such as 5mg + 5mg describe the weights of each material as blended. The quantity of peptide actually present for each component depends on that component’s own net content, so when net contents differ, the ratio of peptide present can differ from the ratio of the stated masses.
What a blend certificate should list
- Every intended component by name and sequence, with its stated mass per vial.
- The method: column chemistry and dimensions, mobile phase, gradient and detection wavelength.
- A chromatogram showing each component’s peak, its retention time and the integration.
- Whether the purity figure is summed or per component, with the value for each component where available.
- An observed mass for each component alongside its expected mass.
- Net peptide content and counter-ion form, per component where determined.
- Vial size and the total stated mass.
How the blends are supplied here
The BPC-157 + TB500 + MGF Blend 18.5mg and the CJC1295 + Ipamorelin Blend 10mg are each supplied as a lyophilised powder in a sealed vial and analysed by independent reverse-phase HPLC, with the result published for that product. The per-component split and vial size are listed on the product page. Vials carry no batch or lot numbers; each vial is matched to its published test by crimp and cap colour.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.